WO1986005981A1 - Treatment of non-ulcer dyspepsia with bismuth salts - Google Patents

Treatment of non-ulcer dyspepsia with bismuth salts Download PDF

Info

Publication number
WO1986005981A1
WO1986005981A1 PCT/AU1986/000106 AU8600106W WO8605981A1 WO 1986005981 A1 WO1986005981 A1 WO 1986005981A1 AU 8600106 W AU8600106 W AU 8600106W WO 8605981 A1 WO8605981 A1 WO 8605981A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibiotics
ulcer dyspepsia
bismuth salt
treatment
antibiotic
Prior art date
Application number
PCT/AU1986/000106
Other languages
French (fr)
Inventor
Thomas Julius Borody
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3771057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1986005981(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Borody Thomas J filed Critical Borody Thomas J
Publication of WO1986005981A1 publication Critical patent/WO1986005981A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • Non-ulcer dyspepsia has not been widely recognised in the past as being a single disease process and has been considered as comprising various disorders with such names as "nervous dyspepsia", “irritable bowel syndrome”, “gastritis”, and also "post-cholecystectomy syndrome".
  • Non-ulcer dyspepsia is characterised by epigastric discomfort, burning or pain, abdominal distention, bloating, belching or burping, nausea, and frequently it is said that the ingestion of food can precipitate such symptoms.
  • the present invention relates to a method of treating non-ulcer dyspepsia in patients suffering from the said non-ulcer dyspepsia, comprising administering to the said patients an effective amount of a pharmaceutically acceptable bismuth salt.
  • a preferred bismuth compound for the treatment of non- * ⁇ lcer dyspepsia is tripotassium dicitratobismuthate. This is also known as De-Nol (Registered Trade Mark). Other bismuth compounds known for the treatment of ulcer and other diseases may also be used in the present invention. Ideally, the bismuth salt is administered orally for a period of at least four (4) weeks and may be administered alone in an adequate dose or in combination with other antibiotics.
  • antibiotics may be chosen from the classes consisting of ⁇ -lactams, such as penicillins; macrolide antibiotics; tetracycline antibiotics and nitro-imidazole sulfones. From within these classes Amoxycillin, Erythromycin, Tetracycline and Tinidazole have been found to be particularly efficacious.
  • Another aspect of the invention comprises a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable bismuth salt, an antibiotic and pharmaceutieally acceptable carrier or diluent.
  • the bismuth salt is tripotassium dicitrato-bismuthate.
  • the most preferable antibiotics are selected from the classes specified above.
  • the ⁇ -lactam antibiotics Most preferably, the antibiotic is Amoxycillin.
  • the pharmaceutical composition is preferably presented in a form suitable for peroral administration, such as liquid, tablet or capsule form.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Treatment of non-ulcer dyspepsia associated with Campylobacter pyloridis infection by the administration of bismuth salts. The administration of bismuth salts in association with antibiotics has been found to be particularly efficacious. A pharmaceutical composition for use in the performance of the present invention is also disclosed.

Description

TREATMENT OF NON-ULCER DYSPEPSIA WITH BISMUTH SALTS BACKGROUND ART This invention relates to a method of treating non-ulcer dyspepsia . In the past bismuth compounds have been used in the treatment of dyspepsia arising from peptic ulcers. However, there has been previously no recognised therapy for the treatment of non-ulcer dyspepsia. Non-ulcer dyspepsia has not been widely recognised in the past as being a single disease process and has been considered as comprising various disorders with such names as "nervous dyspepsia", "irritable bowel syndrome", "gastritis", and also "post-cholecystectomy syndrome". Non-ulcer dyspepsia is characterised by epigastric discomfort, burning or pain, abdominal distention, bloating, belching or burping, nausea, and frequently it is said that the ingestion of food can precipitate such symptoms.
The treatment of this disorder has, until now, been non-specific, empirical and generally inadequate.
It has now been discovered that a new class of sp.iral bacteria reside in the stomach of humans. These bacteria have been found to be closely associated with the presence of gastritis. It has now also been found that the symptoms of non-ulcer dyspepsia are closely related to the presence of the newly discovered spiral bacteria. These bacteria are Campylobacter-like bacteria, currently called Campylobacter pyloridis.
While the use of bismuth salts to treat ulcers has been known, their utility in the treatment of non-ulcer dyspepsia has not been suspected previously. The symptoms of the two conditions are generally different, but may at times overlap. The diagnosis is made endoscopically.
DISCLOSURE OF THE INVENTION The present invention relates to a method of treating non-ulcer dyspepsia in patients suffering from the said non-ulcer dyspepsia, comprising administering to the said patients an effective amount of a pharmaceutically acceptable bismuth salt.
A preferred bismuth compound for the treatment of non-*αlcer dyspepsia is tripotassium dicitratobismuthate. This is also known as De-Nol (Registered Trade Mark). Other bismuth compounds known for the treatment of ulcer and other diseases may also be used in the present invention. Ideally, the bismuth salt is administered orally for a period of at least four (4) weeks and may be administered alone in an adequate dose or in combination with other antibiotics.
It has further been found that the treatment of non-ulcer dyspepsia with bismuth salt is enhanced by the concurrent administration of an antibiotic.
Particularly suitable antibiotics may be chosen from the classes consisting of β-lactams, such as penicillins; macrolide antibiotics; tetracycline antibiotics and nitro-imidazole sulfones. From within these classes Amoxycillin, Erythromycin, Tetracycline and Tinidazole have been found to be particularly efficacious.
Another aspect of the invention comprises a pharmaceutical composition comprising a pharmaceutically acceptable bismuth salt, an antibiotic and pharmaceutieally acceptable carrier or diluent.
Preferably the bismuth salt is tripotassium dicitrato-bismuthate.
The most preferable antibiotics are selected from the classes specified above. In particular, the β-lactam antibiotics. Most preferably, the antibiotic is Amoxycillin. The pharmaceutical composition is preferably presented in a form suitable for peroral administration, such as liquid, tablet or capsule form.
BEST MODE OF CARRYING OUT THE INVENTION The invention will now be further described with reference to the following examples. Example 1
27 Patients suffering from non-ulcer dyspepsia associated with C.pyloridis infection were treated with the bismuth salt, tripotassium dicitrato-bismuthate, known under the registered Trade Mark "De-Nol". All patients were administered 107.7mg De-Nol four times daily. Of the 27, 6 were treated with De-Nol alone. Of these it was found that 40% were completely clear of dyspepsia after 1 month and 60% after two months. The remaining patients were treated with combinations of De-Nol and the antibiotics Amoxycillin and Tinidazole. 250mg Amoxycillin was administered four times daily for four weeks and lgm Tinidazole was administered daily for 10 days. The results were 95% clear completely within 4 weeks. Rebiopsy of the completely clear patients, performed 2 weeks after the four week treatment ceased, showed that the patients remained completely clear.
Trials with Amoxycillin alone indicate that Amoxycillin has no appreciable effect in the treatment of dyspepsia. Example 2
The following pharmaceutical formulation is proposed for use in the performance of the present invention: Tablet formulation tripotassium dicitrato-bismuthate 107.7mg amoxycillin 250 mg magnesium.stearate 10 mg maize starch 20 mg
Flavouring substances may be added as required. It will be clear to those skilled in the art that other formulations falling within the scope of the present invention are possible, and that the invention is therefore not restricted to the above formulation.

Claims

1. A method of treating non-ulcer dyspepsia in patients suffering from non-ulcer dyspepsia associated with Campylobacter pyloridis infection, comprising administering to said patients an effective amount of a pharmaceutically acceptable bismuth salt.
2. A method according to claim 1 wherein the bismuth salt is tripotassium dicitrato-bismuthate.
3. A method according to claim 1 wherein the bismuth salt is administered in conjunction with one or more antibiotics.
4. A method according to claim 3 wherein the antibiotics are selected from the β-lactam antibiotics, macrolide anitbiotics, tetracycline antibiotics and nitro-imidazole sul ones.
5. A method according to claim 4 wherein the antibiotics are selected from Amoxycillin, Tinidazole, Erythromycin and Tetracycline.
6. A method according to claim 5 wherein Amoxycillin and Tinidazole are administered in conjunction with the bismuth salt.
7. A method of treating non-ulcer dyspepsia in patients suffering from non-ulcer dyspepsia, substantially as hereinbefore described with reference to the examples.
8. A pharmaceutical composition comprising a pharmaceutically acceptable bismuth salt, an antibiotic and a pharmaceutically acceptable carrier or diluent.
9. A pharmaceutical composition according to claim 8 wherein the bismuth salt is tripotassium dicitrato-bismuthate.
10. A pharmaceutical composition according to either one of claims 8 or 9 wherein the antibiotic is a β-lactam antibiotic.
11. A pharmaceutical formulation according to claim 10 wherein the antibiotic is Amoxycillin.
12. A pharmaceutical formulation substantially as hereinbefore described with reference to the examples.
PCT/AU1986/000106 1985-04-18 1986-04-18 Treatment of non-ulcer dyspepsia with bismuth salts WO1986005981A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPH0198 1985-04-18
AUPH019885 1985-04-18

Publications (1)

Publication Number Publication Date
WO1986005981A1 true WO1986005981A1 (en) 1986-10-23

Family

ID=3771057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1986/000106 WO1986005981A1 (en) 1985-04-18 1986-04-18 Treatment of non-ulcer dyspepsia with bismuth salts

Country Status (5)

Country Link
EP (1) EP0222834A4 (en)
JP (1) JPS62502967A (en)
AU (1) AU590578B2 (en)
SG (1) SG72632A1 (en)
WO (1) WO1986005981A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
EP0375068A1 (en) * 1988-12-23 1990-06-27 Gist-Brocades N.V. Combining bismuth compounds and tetracyclines
EP0403048A2 (en) * 1989-06-14 1990-12-19 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
EP0439453A4 (en) * 1987-10-12 1991-02-15 Borody Thomas J Improved method for treatment of gastrointestinal disorders.
EP0437294A1 (en) * 1990-01-09 1991-07-17 Yamanouchi Europe B.V. Oral pharmaceutical compositions in unit dosage form
EP0445743A2 (en) * 1990-03-07 1991-09-11 Pliva Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija S P.O. Complexes and chelates of azithromycin as antiulcer drugs
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
US5286492A (en) * 1990-05-03 1994-02-15 Reckitt & Colman Products Limited Method of treatment of Heliobacter pylori infections with triclosan
EP0624373A1 (en) * 1993-05-11 1994-11-17 Spirig Ag Pharmazeutische Präparate Pharmaceutical preparation containing bismuth and amoxycillin and its use
US5403830A (en) * 1987-03-09 1995-04-04 The Proctor & Gamble Company Compositions and methods of treating gastrointestinal disorders
US5407688A (en) * 1987-03-09 1995-04-18 The Procter & Gamble Company Compositions and methods for treating gastrointestinal disorders
WO1996035436A1 (en) * 1995-05-09 1996-11-14 The Procter & Gamble Company Compositions comprising bismuth and one or more antimicrobials, for the treatment and prevention of gastrointestinal disorders
WO1997020567A1 (en) * 1995-12-07 1997-06-12 The Procter & Gamble Company Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders
WO1997020568A1 (en) * 1995-12-07 1997-06-12 The Procter & Gamble Company Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders
WO1997020565A1 (en) * 1995-12-07 1997-06-12 The Procter & Gamble Company Compositions, containing bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders
AT403656B (en) * 1991-09-20 1998-04-27 Glaxo Group Ltd PHARMACEUTICAL COMPOSITION
US6258376B1 (en) 1994-05-02 2001-07-10 Josman Laboratories, Inc. Method of making chewing gum containing colloidal bismuth subcitrate
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6902738B2 (en) 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US7993682B2 (en) 2002-03-04 2011-08-09 Thomas Julius Borody Electrolyte purgative
US10092573B2 (en) 2010-12-13 2018-10-09 Salix Pharmaceuticals, Inc. Gastric and colonic formulations and methods for making and using them
US10166219B2 (en) 2012-07-27 2019-01-01 Redhill Bipharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650504T2 (en) * 1985-06-13 1996-10-31 Marshall Barry James Methods and compositions for the treatment of gastrointestinal disorders
AU623868B2 (en) * 1987-10-12 1992-05-28 Capability Services Pty. Limited Improved method for treatment of gastrointestinal disorders

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6063965A (en) * 1965-06-25 1967-01-05 Morton W. Scott Belayed acting compositions
FR2029402A1 (en) * 1969-01-28 1970-10-23 Breive Et Son Jib Labo Regulation of digestion in gastro intestinal - passage
GB1220819A (en) * 1968-04-24 1971-01-27 Mar Pha Soc D Etude Et D Expl Improved bismuth salt
FR2053002A1 (en) * 1969-06-21 1971-04-16 Clin Midy Bismuth slats of alpha methiminobenzyl - penicillin
FR2073254A2 (en) * 1969-12-04 1971-10-01 Dausse Laboratoire Gum guar stabilised suspensions - of insoluble medicaments for treati gastrointestinal disorders
FR2092636A1 (en) * 1970-06-03 1972-01-28 Griffon Henri Dried yeast - bismuth subnitrate compositions - for gastrointestinal disorders
AU438147B2 (en) * 1968-04-18 1973-07-18 Richard Brown Garland Antacid composition
AU440535B2 (en) * 1969-12-18 1973-09-17 Export Drugs Company Antacid compositions
AU443154B2 (en) * 1968-04-05 1973-11-28 Smithkline & French Laboratories Concentrated liquid antacid compositions
AU485660B2 (en) * 1974-01-18 1977-07-28 Gist-Brocades N.V. Bismuth containing anti-ulcer compositions in solid form
US4153685A (en) * 1968-11-23 1979-05-08 Schering Corporation Bismuth complex preparations
AU521699B2 (en) * 1978-02-24 1982-04-22 Novex Talamanyfejlesz To Es Solid oral pharmaceutical product
AU8950382A (en) * 1981-09-22 1983-04-08 Brocades Pharma B.V. Bismuth containing composition and method for the preparationthereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588589A (en) * 1983-10-13 1986-05-13 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
DE3650504T2 (en) * 1985-06-13 1996-10-31 Marshall Barry James Methods and compositions for the treatment of gastrointestinal disorders
ATE79264T1 (en) * 1985-06-13 1992-08-15 Barry James M D Marshall USE OF BISMUTH IN THE MANUFACTURE OF MEDICATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS CAUSED BY CAMPYLOBACTER POLYRIDIS.

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6063965A (en) * 1965-06-25 1967-01-05 Morton W. Scott Belayed acting compositions
AU443154B2 (en) * 1968-04-05 1973-11-28 Smithkline & French Laboratories Concentrated liquid antacid compositions
AU438147B2 (en) * 1968-04-18 1973-07-18 Richard Brown Garland Antacid composition
GB1220819A (en) * 1968-04-24 1971-01-27 Mar Pha Soc D Etude Et D Expl Improved bismuth salt
US4153685A (en) * 1968-11-23 1979-05-08 Schering Corporation Bismuth complex preparations
FR2029402A1 (en) * 1969-01-28 1970-10-23 Breive Et Son Jib Labo Regulation of digestion in gastro intestinal - passage
FR2053002A1 (en) * 1969-06-21 1971-04-16 Clin Midy Bismuth slats of alpha methiminobenzyl - penicillin
FR2073254A2 (en) * 1969-12-04 1971-10-01 Dausse Laboratoire Gum guar stabilised suspensions - of insoluble medicaments for treati gastrointestinal disorders
AU440535B2 (en) * 1969-12-18 1973-09-17 Export Drugs Company Antacid compositions
FR2092636A1 (en) * 1970-06-03 1972-01-28 Griffon Henri Dried yeast - bismuth subnitrate compositions - for gastrointestinal disorders
AU485660B2 (en) * 1974-01-18 1977-07-28 Gist-Brocades N.V. Bismuth containing anti-ulcer compositions in solid form
AU521699B2 (en) * 1978-02-24 1982-04-22 Novex Talamanyfejlesz To Es Solid oral pharmaceutical product
AU8950382A (en) * 1981-09-22 1983-04-08 Brocades Pharma B.V. Bismuth containing composition and method for the preparationthereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198314, Derwent World Patents Index; AN 1983-34494 *
MARTINDALE, 'The Extra Pharmacopoeia', 28th Edition, published 1982, by The Pharmaceutical Press (London), see pages 927 to 930 *
See also references of EP0222834A4 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403830A (en) * 1987-03-09 1995-04-04 The Proctor & Gamble Company Compositions and methods of treating gastrointestinal disorders
US5407688A (en) * 1987-03-09 1995-04-18 The Procter & Gamble Company Compositions and methods for treating gastrointestinal disorders
EP0439453A4 (en) * 1987-10-12 1991-02-15 Borody Thomas J Improved method for treatment of gastrointestinal disorders.
EP0439453A1 (en) * 1987-10-12 1991-08-07 Borody Thomas J Improved method for treatment of gastrointestinal disorders.
JP2733849B2 (en) * 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス Improved method for treating gastrointestinal disorders
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
EP0375068A1 (en) * 1988-12-23 1990-06-27 Gist-Brocades N.V. Combining bismuth compounds and tetracyclines
EP0403048A2 (en) * 1989-06-14 1990-12-19 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
EP0437294A1 (en) * 1990-01-09 1991-07-17 Yamanouchi Europe B.V. Oral pharmaceutical compositions in unit dosage form
EP0445743A2 (en) * 1990-03-07 1991-09-11 Pliva Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija S P.O. Complexes and chelates of azithromycin as antiulcer drugs
EP0445743A3 (en) * 1990-03-07 1992-10-07 Pliva Pharm & Chem Works Complexes and chelates of azithromycin as antiulcer drugs
US5286492A (en) * 1990-05-03 1994-02-15 Reckitt & Colman Products Limited Method of treatment of Heliobacter pylori infections with triclosan
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
AT403656B (en) * 1991-09-20 1998-04-27 Glaxo Group Ltd PHARMACEUTICAL COMPOSITION
EP0624373A1 (en) * 1993-05-11 1994-11-17 Spirig Ag Pharmazeutische Präparate Pharmaceutical preparation containing bismuth and amoxycillin and its use
US6902738B2 (en) 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6616938B2 (en) 1994-05-02 2003-09-09 Josman Laboratories, Inc. Method of making chewing gum containing colloidal bismuth subcitrate
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6258376B1 (en) 1994-05-02 2001-07-10 Josman Laboratories, Inc. Method of making chewing gum containing colloidal bismuth subcitrate
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
WO1996035436A1 (en) * 1995-05-09 1996-11-14 The Procter & Gamble Company Compositions comprising bismuth and one or more antimicrobials, for the treatment and prevention of gastrointestinal disorders
WO1997020565A1 (en) * 1995-12-07 1997-06-12 The Procter & Gamble Company Compositions, containing bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders
WO1997020568A1 (en) * 1995-12-07 1997-06-12 The Procter & Gamble Company Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders
WO1997020567A1 (en) * 1995-12-07 1997-06-12 The Procter & Gamble Company Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders
US7993682B2 (en) 2002-03-04 2011-08-09 Thomas Julius Borody Electrolyte purgative
US8679549B2 (en) 2002-03-04 2014-03-25 Thomas Julius Borody Electrolyte purgative
US10092573B2 (en) 2010-12-13 2018-10-09 Salix Pharmaceuticals, Inc. Gastric and colonic formulations and methods for making and using them
US10166219B2 (en) 2012-07-27 2019-01-01 Redhill Bipharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation

Also Published As

Publication number Publication date
AU590578B2 (en) 1989-11-09
AU5902686A (en) 1986-11-05
SG72632A1 (en) 2000-05-23
EP0222834A4 (en) 1989-10-04
JPS62502967A (en) 1987-11-26
EP0222834A1 (en) 1987-05-27

Similar Documents

Publication Publication Date Title
AU590578B2 (en) Treatment of non-ulcer dyspepsia with bismuth salts
US5256684A (en) Methods and compositions for the treatment of gastrointestinal disorders
CA1277232C (en) Methods and compositions for the treatment of gastrointestinal disorders
US5601848A (en) Methods for the treatment of gastrointestinal disorders
US5629297A (en) Medicament for treating gastrointestinal disorders
CA2344308C (en) Taurolidine and/or taurultam against infectious ulcer or gastritis
EP0544760B1 (en) Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
Hewitt The penicillins: a review of strategy and tactics
KR100550839B1 (en) Antimicrobials
EP0219912B1 (en) The use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
Labenz et al. High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease
US5229380A (en) Method for treating helicobacter pylori gastritis
Glupczynski In vitro susceptibility of Helicobacter pylori to antibiotics and bismuth salts and the importance of acquired resistance to antibiotics in treatment failures of H. pylori infection
EP0865286B1 (en) Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders
WO1994027579A1 (en) Ulcer treating composition
RU2187318C2 (en) Method of healing chronic gastritis and duodenum ulcer disease
RU2076708C1 (en) Pharmaceutical composition and method of gastroenteric sickness treatment and prophylaxis
Byakod et al. Clinical evaluation of lincomycin, a new antibiotic
O’Morain How to eradicate Helicobacter pylori and prevent reinfection
JPH0920668A (en) Antibacterial agent for helicobacter pylori as slightly aerobic gram-negative bacillus
JPH11246401A (en) Therapeutic agent for helicobacter pylori infectious disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986903120

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1986903120

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1986903120

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1986903120

Country of ref document: EP